But it hadn’t been clear whether those individuals need what doctors call ‘bridging anticoagulation.’ That means taking a different type of anti-clotting medication that is short-acting – – usually heparin. For years, it’s been up to specific doctors and individuals to decide, said Dr. Thomas Ortel, the senior researcher on the new study, and a professor of medication at Duke University Medical Center, in Durham, N.C. ‘We’ve had no clinical trial to reveal whether we need to be [bridging] at all,’ Ortel explained. Now that clinical trial is done. And, it demonstrates for some atrial fibrillation patients, bridging with heparin is definitely unnecessary, Ortel said.This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health Information, an independent news service editorially, is a program of the Kaiser Family Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente. The business use the RTCA Cardio Device to complement their analytical service portfolio for drug development.g. For compilation of preclinical protection data, complements our provider portfolio for the measurement of in vitro toxicity, dermatotoxicity, and chemical-cosmetic screening of substances. For AgenoLAB, the improved qualification and GMP-like validation of prepared processes were the decisive elements to utilize the xCELLigence Cardio System.